Stewart Cole – President, Institut Pasteur, France
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Address: Institut Pasteur
25,28 rue du Docteur Roux
75724 Paris CEDEX 15 – FRANCE
,France
Tel: 33 (0)1 45 68 80 00
Web: http://www.pasteur.fr/ip/easysite/pasteur/en
Since its creation in 1887, the Institut Pasteur has become famous throughout the world as a symbol of science and french culture. For 120 years, our foundation has been contributing to the prevention and treatment of infectious diseases through research, teaching and public health initiatives.
Across the globe, thousands of researchers who have been trained or are working at Institut Pasteur share the values which form the very core of the Pasteurian community: an original scientific approach, an ongoing preoccupation with applying research to public health needs, professional ethics, a desire to care for people regardless of their background or nationality, and an outward-looking attitude, sharing knowledge and expertise with the international community. These guiding principles make the Institut Pasteur a unique institution which values exchanges and partnerships.
The Institut Pasteur enjoys an independent status and has numerous other assets, with its research laboratories, technological platforms, teaching centre and medical centre all located on one campus in the heart of Paris. It also has an international network which currently counts 30 members spread over the five continents.
With its unique setup and prestigious history, the Institut Pasteur has always stood at the forefront of innovation, adapting to the rapidly developing world of biological research and its applications, in particular in the field of biotechnology.
Nowadays, the Institut Pasteur has four priorities to carry out its activities successfully :
– to target its scientific strategy towards infectious diseases, microbiology, virology and immunology;
– to adopt an outward-looking attitude, both within France, through agreements and collaborations with its partners : CNRS (French National Scientific Research Centre), Inserm (French National Institute for Health and Medical Research), universities, hospitals, industrial partners, etc., and at international level with the development of the Réseau International des Instituts Pasteur (International Network of the Institut Pasteur or RIIP), which counts 30 institutes;
– to implement transversal research programs on ambitious themes and led by young researchers;
– to preserve the foundation’s independence, in particular through increased resources from sponsorship and donations.
These priorities, upholding the traditional tasks and values of the Institut Pasteur, place it at the cutting edge of the 21st century’s scientific and human challenges.
Scientific Research in infectious diseases, microbiology, virology and immunology
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Dr. Zoubir Harrat heads the Institut Pasteur d’Algérie (IPA), after having spent most of his career with the institution. He talks of the importance to prepare for the healthcare challenges…
Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical production back to Europe has hit a wall, Sanofi’s slow progress towards finally bringing its…
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for their work on COVID-19 vaccines, smaller and lesser-known companies are also playing…
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics…
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it into the world’s top 5 CDMOs, Ipsen’s resilient…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic…
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two…
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th May 2020, effective 1st July. Loew,…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He…
See our Cookie Privacy Policy Here
